Table 2.
Univariate analysis of breast cancer-specific survival and overall survival.
| Characteristics | BCSS | OS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p | HR | 95% CI | p | |
| Age (years) | ||||||
| ≤50 | 1 | 1 | ||||
| >50 | 1.38 | 0.81–2.36 | 0.23 | 3.39 | 2.16–5.31 | <0.001 |
| Race | ||||||
| Others | 1 | 1 | ||||
| White | 0.64 | 0.40–1.02 | 0.061 | 0.98 | 0.69–1.39 | 0.92 |
| Stage | ||||||
| I | 1 | 1 | ||||
| II | 3.19 | 1.36–7.49 | 0.0079 | 1.47 | 1.01–2.16 | 0.046 |
| III | 11.63 | 4.93–27.44 | <0.001 | 3.90 | 2.58–5.88 | <0.001 |
| Tumor stage | ||||||
| T1 | 1 | 1 | ||||
| T2 | 2.08 | 1.03–4.20 | 0.041 | 1.26 | 0.87–1.82 | 0.22 |
| T3 | 4.19 | 1.98–8.45 | 0.0002 | 2.30 | 1.51–3.51 | <0.001 |
| T4 | 9.02 | 4.29–18.95 | <0.001 | 4.31 | 2.78–6.68 | <0.001 |
| Nodal status | ||||||
| N0 | 1 | 1 | ||||
| N1 | 2.89 | 1.79–4.66 | <0.001 | 1.53 | 1.07–2.19 | 0.019 |
| N2-3 | 4.41 | 2.46–7.90 | <0.001 | 2.98 | 1.94–4.57 | <0.001 |
| ER status | ||||||
| Negative | 1 | 1 | ||||
| Positive | 1.27 | 0.74–2.18 | 0.39 | 1.05 | 0.72–1.55 | 0.79 |
| PR status | ||||||
| Negative | 1 | 1 | ||||
| Positive | 0.48 | 0.19–1.19 | 0.11 | 0.48 | 0.27–0.87 | 0.015 |
| Grade | ||||||
| Well-differentiated | 1 | 1 | ||||
| Moderately differentiated | 1.08 | 0.48–2.42 | 0.85 | 0.97 | 0.61–1.53 | 0.89 |
| Poor or undifferentiated | 1.30 | 0.62–2.73 | 0.49 | 0.84 | 0.54–1.29 | 0.42 |
| Chemotherapy | ||||||
| No/unknown | 1 | 1 | ||||
| Yes | 1.19 | 0.81–1.75 | 0.38 | 0.54 | 0.41–0.71 | <0.001 |
| Treatment | ||||||
| LUMP only | 1 | 1 | ||||
| LUMP + RT | 0.29 | 0.11–0.75 | 0.01 | 0.48 | 0.30–0.77 | 0.0023 |
| MAST only | 1.35 | 0.78–2.35 | 0.28 | 1.28 | 0.91–1.81 | 0.15 |
| MAST + RT | 1.51 | 0.79–2.90 | 0.21 | 0.91 | 0.58–1.43 | 0.67 |
MAST, mastectomy; LUMP, lumpectomy; RT, radiotherapy; ER, estrogen receptor; PR, progesterone receptor; BCSS, breast cancer-specific survival; OS, overall survival.